What is the treatment for Diabetes Insipidus (DI) with Desmopressin (DDAVP)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: May 8, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the FDA Drug Label

Desmopressin acetate is a replacement hormone for antidiuretic hormone in the treatment of central diabetes insipidus The antidiuretic effects of desmopressin acetate are mediated by stimulation of vasopressin 2 (V2) receptors, thereby increasing water re-absorption in the kidney, and hence reducing urine production Desmopressin acetate injection 4 mcg/mL is indicated as antidiuretic replacement therapy in the management of central (cranial) diabetes insipidus

Desmopressin is used to treat central diabetes insipidus by replacing the antidiuretic hormone and reducing urine production.

  • It works by stimulating vasopressin 2 (V2) receptors in the kidney to increase water reabsorption.
  • Desmopressin acetate injection is indicated for the management of central diabetes insipidus 1, 2, 1.

From the Research

DDAVP (desmopressin) is the first-line treatment for central diabetes insipidus, with oral administration being a reliable and effective mode of treatment, as evidenced by the most recent study 3. The typical starting dose of oral desmopressin is 0.1-0.4 mg twice daily, which can be titrated based on symptom control and serum sodium levels.

  • Key considerations in treatment include:
    • Controlling polyuria while avoiding hyponatremia
    • Monitoring fluid intake, urine output, and watching for symptoms of water intoxication
    • Adjusting treatment to maintain eunatremic weight and guide day-to-day fluid targets
    • Allowing regular breaks from DDAVP to prevent hyponatremia, as recommended in the most recent study 3
  • The mechanism of action of DDAVP involves binding to V2 receptors in the kidney collecting ducts, increasing water reabsorption by upregulating aquaporin-2 water channels, effectively replacing the deficient hormone in central diabetes insipidus, as described in earlier studies 4, 5, 6, 7.
  • The most recent study 3 highlights the importance of oral DDAVP as a reliable mode of treatment for chronic central diabetes insipidus, replacing nasal DDAVP, and emphasizes the need for careful management to avoid hyponatremia and hypernatraemia.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.